Limaprost, identified by its CAS number 74397 - 12 - 9, is a synthetic prostaglandin E1 derivative with significant therapeutic potential, especially in the treatment of peripheral circulatory disorders and lumbar spinal canal stenosis. As a reliable supplier of Limaprost, I've witnessed its growing demand in the global market. However, understanding its regulatory status in different countries is crucial for both suppliers like me and customers interested in this product.
Regulatory Status in Japan
Japan is where Limaprost was first developed and approved. It has a well - established regulatory framework for pharmaceuticals, and Limaprost has been on the market for several decades. The Japanese regulatory authorities, such as the Pharmaceuticals and Medical Devices Agency (PMDA), have conducted comprehensive clinical trials and safety evaluations before granting approval.
In Japan, Limaprost is indicated for the treatment of lumbar spinal canal stenosis and improves symptoms such as intermittent claudication, numbness, and pain in the lower extremities. The drug is available in oral dosage forms, which are convenient for patients. The strict regulatory environment in Japan ensures that the manufacturing, marketing, and distribution of Limaprost adhere to high - quality standards. Pharmaceutical companies are required to maintain detailed records of production processes, quality control measures, and adverse event reporting.
Regulatory Status in China
In China, the regulatory landscape for pharmaceuticals is evolving rapidly. The National Medical Products Administration (NMPA) is responsible for the approval and supervision of drugs. Limaprost has also gained approval in China for the treatment of certain circulatory disorders.
Chinese regulatory requirements emphasize the need for local clinical trials to assess the efficacy and safety of drugs in the Chinese population. Pharmaceutical companies supplying Limaprost in China must comply with these requirements, which include large - scale, multi - center clinical trials. The NMPA also enforces strict regulations on drug manufacturing facilities, ensuring that they meet Good Manufacturing Practice (GMP) standards. This helps to guarantee the quality and consistency of Limaprost products in the Chinese market.
Regulatory Status in the United States
The United States has one of the most complex and stringent pharmaceutical regulatory systems in the world, overseen by the Food and Drug Administration (FDA). As of now, Limaprost has not received full approval from the FDA for marketing in the United States.
To gain FDA approval, a pharmaceutical company must submit a New Drug Application (NDA) that includes extensive data from pre - clinical studies, clinical trials, manufacturing information, and proposed labeling. The FDA evaluates the safety, efficacy, and quality of the drug based on this data. For Limaprost, the challenges in obtaining FDA approval may include the need for more comprehensive clinical trials in the US population, as well as demonstrating the drug's superiority or non - inferiority compared to existing treatment options.
Regulatory Status in the European Union
The European Medicines Agency (EMA) is responsible for the regulation of pharmaceuticals in the European Union. The regulatory process in the EU involves a centralized or decentralized procedure, depending on the nature of the drug.
For Limaprost, if a company wishes to market the drug across multiple EU member states, it may choose the centralized procedure, which provides a single marketing authorization valid in all EU countries. However, this requires a high - level of scientific evidence from clinical trials and manufacturing data. The EMA also has strict requirements for pharmacovigilance, which means that companies must monitor and report any adverse events associated with Limaprost after it is on the market.
Comparison of Regulatory Requirements
Each country or region has its own unique regulatory requirements for Limaprost. In general, all regulatory authorities focus on the safety, efficacy, and quality of the drug. However, the specific requirements for clinical trials, manufacturing standards, and labeling may vary.


For example, some countries may require more extensive long - term safety data, while others may place more emphasis on the drug's economic impact. Additionally, the cultural and demographic differences between countries may also influence the regulatory decisions. For instance, a drug that is highly effective in one population may need further evaluation in another population to ensure its safety and efficacy.
Importance of Understanding Regulatory Status for Suppliers
As a supplier of Limaprost (CAS 74397 - 12 - 9), understanding the regulatory status in different countries is of utmost importance. It helps us to ensure that our products meet the specific requirements of each market. We need to work closely with pharmaceutical companies and regulatory authorities to provide accurate information about our manufacturing processes, quality control measures, and the results of pre - clinical and clinical studies.
By complying with the regulatory requirements, we can build trust with our customers and expand our market share. We also need to stay updated on any changes in the regulatory environment, as new regulations may affect the production, marketing, and distribution of Limaprost.
Related Products and Their Regulatory Considerations
In addition to Limaprost, there are other prostaglandin - related products that are also subject to regulatory scrutiny. For example, Latanoprost For Human Eye Drops is used in the treatment of glaucoma. Its regulatory status also varies from country to country. The regulatory requirements for eye drops may be different from those for oral medications, as eye drops are directly applied to a sensitive organ.
Another related product is Alfaprostol for Human CAS 74176 - 31 - 1. Similar to Limaprost, Alfaprostol is a prostaglandin derivative. Its regulatory approval is also based on safety, efficacy, and quality evaluations.
Prostaglandins Corey Lactone Diol For Human Use is an important intermediate in the synthesis of prostaglandin - based drugs. Although it may not be a final pharmaceutical product, its production and supply are also regulated to ensure the quality of the final drugs.
Conclusion and Call to Action
In conclusion, the regulatory status of Limaprost (CAS 74397 - 12 - 9) varies significantly from country to country. As a supplier, we are committed to meeting the regulatory requirements of different markets to provide high - quality Limaprost products.
If you are interested in purchasing Limaprost or have any questions about its regulatory status in specific countries, please feel free to contact us for further discussion and potential procurement negotiations. We have a team of experts who can provide you with detailed information and support throughout the procurement process.
References
- "Regulatory Affairs in the Pharmaceutical Industry" by William A. Hutton.
- Publications from the Pharmaceuticals and Medical Devices Agency (PMDA) of Japan.
- Reports from the National Medical Products Administration (NMPA) of China.
- Documents from the Food and Drug Administration (FDA) of the United States.
- Publications from the European Medicines Agency (EMA).






